 |
|
Corticosteroid Requirements in Polymyalgia Rheumatica
Cornelia M. Weyand, MD;
James W. Fulbright, MS;
Jonathan M. Evans, MD;
Gene G. Hunder, MD;
Jörg J. Goronzy, MD, PhD
Arch Intern Med. 1999;159:577-584.
Background Polymyalgia rheumatica (PMR) is a systemic inflammatory disease of unknown cause that affects older individuals. Clinical symptoms respond promptly to corticosteroids, but treatment is often required for several years, frequently resulting in adverse drug effects. Guidelines for the optimal use of corticosteroids that maximize relief of symptoms but minimize adverse effects of the therapy are needed.
Objective To determine whether clinical or laboratory parameters in PMR could be identified that allow for stratifying patients into subsets with differences in corticosteroid requirements.
Patients and Methods We studied 27 patients with PMR treated with a standardized schedule of prednisone. Patients were reevaluated at monthly intervals for pain scores and physician and patient assessments. Plasma interleukin 6 level and the erythrocyte sedimentation rate were measured at each visit. The duration of steroid therapy and the cumulative steroid dose were calculated.
Results Based on the initial response to therapy and the duration of disease, the 27 patients could be subdivided into 3 distinct groups. Eight with low erythrocyte sedimentation rates responded rapidly and required corticosteroids for less than 1 year with rare disease flares on tapering of prednisone. Twelve others responded well initially but did not tolerate reduction to lower doses and had remitting disease of more than 1 year. Seven patients had only a partial response to the initial steroid regimen. After 4 weeks of therapy, the erythrocyte sedimentation rates improved, but levels of interleukin 6 remained elevated. Pretreatment pain scores were also higher in these partial responder patients (P = .05).
Conclusions Polymyalgia rheumatica is a heterogeneous disease with variations in the treatment duration and dose of corticosteroids required for suppression of symptoms. Pretreatment erythrocyte sedimentation rate and nonresponsiveness of interleukin 6 to steroid therapy are helpful in dividing patients into subsets with different treatment requirements.
From the Department of Medicine, Division of Rheumatology, Mayo Clinic and Foundation, Rochester, Minn.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Treatment of Polymyalgia Rheumatica: A Systematic Review
Hernandez-Rodriguez et al.
Arch Intern Med 2009;169:1839-1850.
ABSTRACT
| FULL TEXT
18F-Flourodeoxyglucose positron emission tomography in polymyalgia rheumatica: novel insight into complex pathogenesis but questionable use in predicting relapses
Dejaco et al.
Rheumatology (Oxford) 2007;46:559-560.
FULL TEXT
Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis
Cutolo et al.
Ann Rheum Dis 2006;65:1438-1443.
ABSTRACT
| FULL TEXT
A disease activity score for polymyalgia rheumatica
Leeb and Bird
Ann Rheum Dis 2004;63:1279-1283.
ABSTRACT
| FULL TEXT
Activation of Arterial Wall Dendritic Cells and Breakdown of Self-tolerance in Giant Cell Arteritis
Ma-Krupa et al.
JEM 2004;199:173-183.
ABSTRACT
| FULL TEXT
EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT)
Leeb et al.
Ann Rheum Dis 2003;62:1189-1194.
ABSTRACT
| FULL TEXT
Giant-Cell Arteritis and Polymyalgia Rheumatica
Weyand and Goronzy
ANN INTERN MED 2003;139:505-515.
ABSTRACT
| FULL TEXT
Medium- and Large-Vessel Vasculitis
Weyand and Goronzy
NEJM 2003;349:160-169.
FULL TEXT
Polymyalgia Rheumatica and Giant-Cell Arteritis
Salvarani et al.
NEJM 2002;347:261-271.
FULL TEXT
|
